{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:21:03Z","timestamp":1784956863432,"version":"3.55.0"},"publisher-location":"Cham","reference-count":90,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030657673","type":"print"},{"value":"9783030657680","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":140,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of lymphoid neoplasms with different biological characteristics. About 90% of all lymphomas in the United States originate from B lymphocytes, while the remaining originate from T cells [1]. The treatment of NHLs depends on the neoplastic histology and stage of the tumor, which will indicate whether radiotherapy, chemotherapy, or a combination is the best suitable treatment [2]. The American Cancer Society describes the staging of lymphoma as follows: Stage I is lymphoma in a single node or area. Stage II is when that lymphoma has spread to another node or organ tissue. Stage III is when it has spread to lymph nodes on two sides of the diaphragm. Stage IV is when cancer has significantly spread to organs outside the lymph system. Radiation therapy is the traditional therapeutic route for localized follicular and mucosa-associated lymphomas. Chemotherapy is utilized for the treatment of large-cell lymphomas and high-grade lymphomas [2]. However, the treatment of indolent lymphomas remains problematic as the patients often have metastasis, for which no standard approach exists [2].<\/jats:p>","DOI":"10.1007\/978-3-030-65768-0_7","type":"book-chapter","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T11:20:30Z","timestamp":1621509630000},"page":"103-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-Hodgkin Lymphoma Metabolism"],"prefix":"10.1007","author":[{"given":"Brian James","family":"Kirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Jyuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael James","family":"Betenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"issue":"9844","key":"7_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012). Non-Hodgkin lymphoma. Lancet, 380(9844), 848\u2013857.","journal-title":"Lancet"},{"key":"7_CR2","first-page":"1524","volume":"2016","author":"M Karen","year":"2016","unstructured":"Karen, M., Winkfield, R. W. T., & Gospodarowicz, M. K. (2016). Chapter 77\u2014Non-Hodgkin\u2019s lymphoma. Clinical Radiation Oncology (Fourth Edition), 2016, 1524\u20131546.e7.","journal-title":"Clinical Radiation Oncology (Fourth Edition)"},{"issue":"1","key":"7_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani, R. H., et al. (2013). Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. Journal of Clinical Oncology, 31(1), 88\u201394.","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"7_CR4","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1172\/JCI63186","volume":"122","author":"R Kridel","year":"2012","unstructured":"Kridel, R., Sehn, L. H., & Gascoyne, R. D. (2012). Pathogenesis of follicular lymphoma. The Journal of Clinical Investigation, 122(10), 3424\u20133431.","journal-title":"The Journal of Clinical Investigation"},{"issue":"5","key":"7_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11912-012-0258-4","volume":"14","author":"E Wong","year":"2012","unstructured":"Wong, E., & Dickinson, M. (2012). Transformation in follicular lymphoma: Biology, prognosis, and therapeutic options. Current Oncology Reports, 14(5), 424\u2013432.","journal-title":"Current Oncology Reports"},{"issue":"11","key":"7_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","volume":"123","author":"A Bouska","year":"2014","unstructured":"Bouska, A., et al. (2014). Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood, 123(11), 1681\u20131690.","journal-title":"Blood"},{"issue":"2","key":"7_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun, J., et al. (2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics, 46(2), 176\u2013181.","journal-title":"Nature Genetics"},{"issue":"7","key":"7_CR8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1084\/jem.20132120","volume":"211","author":"E Oricchio","year":"2014","unstructured":"Oricchio, E., et al. (2014). Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. The Journal of Experimental Medicine, 211(7), 1379\u20131391.","journal-title":"The Journal of Experimental Medicine"},{"key":"7_CR9","doi-asserted-by":"publisher","unstructured":"Antonio, M. J., Zhang, C., & Le, A. (2021). Different tumor microenvironments lead to different metabolic phenotypes. Advances in Experimental Medicine and Biology, 1311, https:\/\/doi.org\/10.1007\/978-3-030-65768-0_10","DOI":"10.1007\/978-3-030-65768-0_10"},{"issue":"3","key":"7_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.immuni.2015.09.001","volume":"43","author":"SK Biswas","year":"2015","unstructured":"Biswas, S. K. (2015). Metabolic reprogramming of immune cells in cancer progression. Immunity, 43(3), 435\u2013449.","journal-title":"Immunity"},{"key":"7_CR11","doi-asserted-by":"publisher","unstructured":"Nabi, K., & Le, A. (2021). The intratumoral heterogeneity of cancer metabolism. Advances in Experimental Medicine and Biology, 1311, https:\/\/doi.org\/10.1007\/978-3-030-65768-0_11","DOI":"10.1007\/978-3-030-65768-0_11"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/bs.ircmb.2019.07.003","volume":"347","author":"G Hoang","year":"2019","unstructured":"Hoang, G., Udupa, S., & Le, A. (2019). Application of metabolomics technologies toward cancer prognosis and therapy. International Review of Cell and Molecular Biology, 347, 191\u2013223.","journal-title":"International Review of Cell and Molecular Biology"},{"key":"7_CR13","doi-asserted-by":"publisher","unstructured":"Bose, S., Zhang, C., & Le, A. (2021). Glucose metabolism in cancer: The Warburg effect and beyond. Advances in Experimental Medicine and Biology, 1311, https:\/\/doi.org\/10.1007\/978-3-030-65768-0_1","DOI":"10.1007\/978-3-030-65768-0_1"},{"issue":"1","key":"7_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1148\/radiology.190.1.8259386","volume":"190","author":"JS Newman","year":"1994","unstructured":"Newman, J. S., et al. (1994). Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology, 190(1), 111\u2013116.","journal-title":"Radiology"},{"issue":"3","key":"7_CR15","first-page":"325","volume":"33","author":"J Okada","year":"1992","unstructured":"Okada, J., et al. (1992). Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. Journal of Nuclear Medicine, 33(3), 325\u2013329.","journal-title":"Journal of Nuclear Medicine"},{"issue":"5","key":"7_CR16","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.18632\/oncotarget.6315","volume":"7","author":"L Mediani","year":"2016","unstructured":"Mediani, L., et al. (2016). Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K\/Akt\/mTOR signaling. Oncotarget, 7(5), 5521\u20135537.","journal-title":"Oncotarget"},{"issue":"2","key":"7_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12291-015-0511-3","volume":"31","author":"C Yadav","year":"2016","unstructured":"Yadav, C., et al. (2016). Serum lactate dehydrogenase in non-Hodgkin\u2019s lymphoma: A prognostic indicator. Indian Journal of Clinical Biochemistry, 31(2), 240\u2013242.","journal-title":"Indian Journal of Clinical Biochemistry"},{"issue":"4","key":"7_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000206395","volume":"72","author":"G Fasola","year":"1984","unstructured":"Fasola, G., et al. (1984). Serum LDH concentration in non-Hodgkin\u2019s lymphomas. Relationship to histologic type, tumor mass, and presentation features. Acta Haematologica, 72(4), 231\u2013238.","journal-title":"Acta Haematologica"},{"issue":"2","key":"7_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/bjc.1989.57","volume":"59","author":"RA Cowan","year":"1989","unstructured":"Cowan, R. A., et al. (1989). Prognostic factors in high and intermediate grade non-Hodgkin\u2019s lymphoma. British Journal of Cancer, 59(2), 276\u2013282.","journal-title":"British Journal of Cancer"},{"issue":"5","key":"7_CR20","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1073\/pnas.0914433107","volume":"107","author":"A Le","year":"2010","unstructured":"Le, A., et al. (2010). Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 107(5), 2037\u20132042.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"14","key":"7_CR21","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1158\/0008-5472.CAN-13-0465","volume":"73","author":"P Dutta","year":"2013","unstructured":"Dutta, P., et al. (2013). Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Research, 73(14), 4190\u20134195.","journal-title":"Cancer Research"},{"issue":"1","key":"7_CR22","first-page":"25","volume":"5","author":"WM Claudino","year":"2015","unstructured":"Claudino, W. M., et al. (2015). Type B lactic acidosis: A rare but life threatening hematologic emergency. A case illustration and brief review. American Journal of Blood Research, 5(1), 25\u201329.","journal-title":"American Journal of Blood Research"},{"issue":"3","key":"7_CR23","first-page":"120","volume":"69","author":"R de Groot","year":"2011","unstructured":"de Groot, R., et al. (2011). Type B lactic acidosis in solid malignancies. The Netherlands Journal of Medicine, 69(3), 120\u2013123.","journal-title":"The Netherlands Journal of Medicine"},{"issue":"4","key":"7_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0011-5029(89)90021-7","volume":"35","author":"BA Mizock","year":"1989","unstructured":"Mizock, B. A. (1989). Lactic acidosis. Disease-a-Month, 35(4), 233\u2013300.","journal-title":"Disease-a-Month"},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1100\/tsw.2011.125","volume":"11","author":"JP Ruiz","year":"2011","unstructured":"Ruiz, J. P., Singh, A. K., & Hart, P. (2011). Type B lactic acidosis secondary to malignancy: Case report, review of published cases, insights into pathogenesis, and prospects for therapy. ScientificWorldJournal, 11, 1316\u20131324.","journal-title":"ScientificWorldJournal"},{"issue":"5","key":"7_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/BF02849863","volume":"22","author":"E Dogan","year":"2005","unstructured":"Dogan, E., et al. (2005). Fatal lactic acidosis due to leukemic transformation in a patient with non-Hodgkin\u2019s lymphoma: Case report. Advances in Therapy, 22(5), 443\u2013446.","journal-title":"Advances in Therapy"},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"534561","DOI":"10.1155\/2009\/534561","volume":"2009","author":"FH Chan","year":"2009","unstructured":"Chan, F. H., Carl, D., & Lyckholm, L. J. (2009). Severe lactic acidosis in a patient with B-cell lymphoma: A case report and review of the literature. Case Reports in Medicine, 2009, 534561.","journal-title":"Case Reports in Medicine"},{"issue":"10","key":"7_CR28","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.mayocp.2013.06.012","volume":"88","author":"LW Andersen","year":"2013","unstructured":"Andersen, L. W., et al. (2013). Etiology and therapeutic approach to elevated lactate levels. Mayo Clinic Proceedings, 88(10), 1127\u20131140.","journal-title":"Mayo Clinic Proceedings"},{"issue":"3","key":"7_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2013.03.036","volume":"62","author":"P Sia","year":"2013","unstructured":"Sia, P., Plumb, T. J., & Fillaus, J. A. (2013). Type B lactic acidosis associated with multiple myeloma. American Journal of Kidney Diseases, 62(3), 633\u2013637.","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"7_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis, R. J., & Chandel, N. S. (2016). Fundamentals of cancer metabolism. Science Advances, 2(5), e1600200.","journal-title":"Science Advances"},{"issue":"10","key":"7_CR31","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine, Z. E., et al. (2015). MYC, metabolism, and cancer. Cancer Discovery, 5(10), 1024\u20131039.","journal-title":"Cancer Discovery"},{"issue":"2","key":"7_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M., & Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell, 149(2), 274\u2013293.","journal-title":"Cell"},{"issue":"21","key":"7_CR33","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-09-0889","volume":"15","author":"CV Dang","year":"2009","unstructured":"Dang, C. V., Le, A., & Gao, P. (2009). MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clinical Cancer Research, 15(21), 6479\u20136483.","journal-title":"Clinical Cancer Research"},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-62703-429-6_14","volume":"1012","author":"A Le","year":"2013","unstructured":"Le, A., & Dang, C. V. (2013). Studying Myc\u2019s role in metabolism regulation. Methods in Molecular Biology, 1012, 213\u2013219.","journal-title":"Methods in Molecular Biology"},{"key":"7_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/genes8040115","volume":"8","author":"P Korac","year":"2017","unstructured":"Korac, P., et al. (2017). Role of MYC in B cell lymphomagenesis. Genes (Basel), 8, 4.","journal-title":"Genes (Basel)"},{"issue":"2","key":"7_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"Cairns, R. A., Harris, I. S., & Mak, T. W. (2011). Regulation of cancer cell metabolism. Nature Reviews. Cancer, 11(2), 85\u201395.","journal-title":"Nature Reviews. Cancer"},{"key":"7_CR37","doi-asserted-by":"publisher","unstructured":"Li, T., Copeland, C., & Le, A. (2021). Glutamine metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https:\/\/doi.org\/10.1007\/978-3-030-65768-0_2","DOI":"10.1007\/978-3-030-65768-0_2"},{"issue":"14","key":"7_CR38","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/onc.2016.360","volume":"36","author":"TQ Tran","year":"2017","unstructured":"Tran, T. Q., et al. (2017). Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene, 36(14), 1991\u20132001.","journal-title":"Oncogene"},{"issue":"29","key":"7_CR39","doi-asserted-by":"publisher","first-page":"11818","DOI":"10.1073\/pnas.1205995109","volume":"109","author":"AP Bhatt","year":"2012","unstructured":"Bhatt, A. P., et al. (2012). Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 109(29), 11818\u201311823.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"7_CR40","doi-asserted-by":"crossref","unstructured":"Park, J. K., et al. (2021). The heterogeneity of lipid metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https:\/\/doi.org\/10.1007\/978-3-030-65768-0_3.","DOI":"10.1007\/978-3-030-65768-0_3"},{"issue":"22","key":"7_CR41","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1182\/blood-2009-10-251082","volume":"115","author":"AP Bhatt","year":"2010","unstructured":"Bhatt, A. P., et al. (2010). Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K\/Akt\/mTOR-addicted lymphomas. Blood, 115(22), 4455\u20134463.","journal-title":"Blood"},{"issue":"10","key":"7_CR42","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.bcp.2006.08.009","volume":"72","author":"AC Faber","year":"2006","unstructured":"Faber, A. C., et al. (2006). Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochemical Pharmacology, 72(10), 1246\u20131256.","journal-title":"Biochemical Pharmacology"},{"issue":"5","key":"7_CR43","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-06-028092","volume":"109","author":"SH Sin","year":"2007","unstructured":"Sin, S. H., et al. (2007). Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood, 109(5), 2165\u20132173.","journal-title":"Blood"},{"issue":"7400","key":"7_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature11066","volume":"485","author":"SM Jeon","year":"2012","unstructured":"Jeon, S. M., Chandel, N. S., & Hay, N. (2012). AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 485(7400), 661\u2013665.","journal-title":"Nature"},{"issue":"4","key":"7_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","volume":"22","author":"P Caro","year":"2012","unstructured":"Caro, P., et al. (2012). Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell, 22(4), 547\u2013560.","journal-title":"Cancer Cell"},{"issue":"2","key":"7_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young, R. M., et al. (2015). B-cell receptor signaling in diffuse large B-cell lymphoma. Seminars in Hematology, 52(2), 77\u201385.","journal-title":"Seminars in Hematology"},{"issue":"8","key":"7_CR47","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","volume":"130","author":"O Havranek","year":"2017","unstructured":"Havranek, O., et al. (2017). Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood, 130(8), 995\u20131006.","journal-title":"Blood"},{"issue":"1","key":"7_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn, U. E., et al. (2017). Cancer metabolism: A therapeutic perspective. Nature Reviews. Clinical Oncology, 14(1), 11\u201331.","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"5","key":"7_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","volume":"11","author":"PM Wilson","year":"2014","unstructured":"Wilson, P. M., et al. (2014). Standing the test of time: Targeting thymidylate biosynthesis in cancer therapy. Nature Reviews. Clinical Oncology, 11(5), 282\u2013298.","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"3","key":"7_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.hoc.2012.02.002","volume":"26","author":"M Visentin","year":"2012","unstructured":"Visentin, M., Zhao, R., & Goldman, I. D. (2012). The antifolates. Hematology\/Oncology Clinics of North America, 26(3), 629\u2013648. ix.","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"3","key":"7_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00109-011-0730-x","volume":"89","author":"CV Dang","year":"2011","unstructured":"Dang, C. V., et al. (2011). Therapeutic targeting of cancer cell metabolism. Journal of Molecular Medicine (Berlin), 89(3), 205\u2013212.","journal-title":"Journal of Molecular Medicine (Berlin)"},{"issue":"5","key":"7_CR52","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2014.03.052","volume":"157","author":"JT Cunningham","year":"2014","unstructured":"Cunningham, J. T., et al. (2014). Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell, 157(5), 1088\u20131103.","journal-title":"Cell"},{"issue":"2","key":"7_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K Duvel","year":"2010","unstructured":"Duvel, K., et al. (2010). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Molecular Cell, 39(2), 171\u2013183.","journal-title":"Molecular Cell"},{"issue":"3","key":"7_CR54","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0899-9007(99)00266-X","volume":"16","author":"FP Kuhajda","year":"2000","unstructured":"Kuhajda, F. P. (2000). Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition, 16(3), 202\u2013208.","journal-title":"Nutrition"},{"issue":"1","key":"7_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2184.2007.00498.x","volume":"41","author":"A Vazquez-Martin","year":"2008","unstructured":"Vazquez-Martin, A., et al. (2008). Overexpression of fatty acid synthase gene activates HER1\/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Proliferation, 41(1), 59\u201385.","journal-title":"Cell Proliferation"},{"issue":"4","key":"7_CR56","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/fon.10.11","volume":"6","author":"R Flavin","year":"2010","unstructured":"Flavin, R., et al. (2010). Fatty acid synthase as a potential therapeutic target in cancer. Future Oncology, 6(4), 551\u2013562.","journal-title":"Future Oncology"},{"issue":"10","key":"7_CR57","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/leu.2009.117","volume":"23","author":"P Gasperini","year":"2009","unstructured":"Gasperini, P., & Tosato, G. (2009). Targeting the mammalian target of rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia, 23(10), 1867\u20131874.","journal-title":"Leukemia"},{"key":"7_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fonc.2016.00135","volume":"6","author":"AA Shestov","year":"2016","unstructured":"Shestov, A. A., et al. (2016). (13)C MRS and LC-MS flux analysis of tumor intermediary metabolism. Frontiers in Oncology, 6, 135.","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"7_CR59","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/0008-5472.CAN-09-3556","volume":"70","author":"CV Dang","year":"2010","unstructured":"Dang, C. V. (2010). Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Research, 70(3), 859\u2013862.","journal-title":"Cancer Research"},{"issue":"3","key":"7_CR60","doi-asserted-by":"publisher","first-page":"e1798","DOI":"10.1371\/journal.pone.0001798","volume":"3","author":"J Kim","year":"2008","unstructured":"Kim, J., Lee, J. H., & Iyer, V. R. (2008). Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One, 3(3), e1798.","journal-title":"PLoS One"},{"issue":"21","key":"7_CR61","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1128\/MCB.00440-07","volume":"27","author":"JW Kim","year":"2007","unstructured":"Kim, J. W., et al. (2007). Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Molecular and Cellular Biology, 27(21), 7381\u20137393.","journal-title":"Molecular and Cellular Biology"},{"issue":"14","key":"7_CR62","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1128\/MCB.25.14.6225-6234.2005","volume":"25","author":"F Li","year":"2005","unstructured":"Li, F., et al. (2005). Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Molecular and Cellular Biology, 25(14), 6225\u20136234.","journal-title":"Molecular and Cellular Biology"},{"issue":"2","key":"7_CR63","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cmet.2011.06.011","volume":"14","author":"CD Folmes","year":"2011","unstructured":"Folmes, C. D., et al. (2011). Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metabolism, 14(2), 264\u2013271.","journal-title":"Cell Metabolism"},{"issue":"1","key":"7_CR64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","volume":"15","author":"A Le","year":"2012","unstructured":"Le, A., et al. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metabolism, 15(1), 110\u2013121.","journal-title":"Cell Metabolism"},{"issue":"5","key":"7_CR65","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/acsmedchemlett.6b00060","volume":"7","author":"SC Zimmermann","year":"2016","unstructured":"Zimmermann, S. C., et al. (2016). Allosteric glutaminase inhibitors based on a 1,4-di(5-amino-1,3,4-thiadiazol-2-yl)butane scaffold. ACS Medicinal Chemistry Letters, 7(5), 520\u2013524.","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"23","key":"7_CR66","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1073\/pnas.1203244109","volume":"109","author":"W Liu","year":"2012","unstructured":"Liu, W., et al. (2012). Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proceedings of the National Academy of Sciences of the United States of America, 109(23), 8983\u20138988.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"7_CR67","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrc2540","volume":"8","author":"JA Bertout","year":"2008","unstructured":"Bertout, J. A., Patel, S. A., & Simon, M. C. (2008). The impact of O2 availability on human cancer. Nature Reviews. Cancer, 8(12), 967\u2013975.","journal-title":"Nature Reviews. Cancer"},{"issue":"12","key":"7_CR68","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.exphem.2010.08.007","volume":"38","author":"Q Qiao","year":"2010","unstructured":"Qiao, Q., et al. (2010). NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma. Experimental Hematology, 38(12), 1199\u20131208.","journal-title":"Experimental Hematology"},{"issue":"11","key":"7_CR69","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R., et al. (2014). Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine, 370(11), 997\u20131007.","journal-title":"The New England Journal of Medicine"},{"key":"7_CR70","first-page":"491","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang, L., et al. (2019). Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine, 11, 491.","journal-title":"Science Translational Medicine"},{"key":"7_CR71","doi-asserted-by":"publisher","first-page":"14920","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao, X., et al. (2017). Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nature Communications, 8, 14920.","journal-title":"Nature Communications"},{"issue":"9","key":"7_CR72","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron, D., et al. (2014). Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discovery, 4(9), 1022\u20131035.","journal-title":"Cancer Discovery"},{"issue":"22","key":"7_CR73","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl, B. S., et al. (2014). A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood, 123(22), 3398\u20133405.","journal-title":"Blood"},{"issue":"23","key":"7_CR74","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess, G., et al. (2009). Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 27(23), 3822\u20133829.","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"7_CR75","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig, T. E., et al. (2005). Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Journal of Clinical Oncology, 23(23), 5347\u20135356.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"7_CR76","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.leukres.2008.06.010","volume":"33","author":"MG Garcia","year":"2009","unstructured":"Garcia, M. G., et al. (2009). PI3K\/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leukemia Research, 33(2), 288\u2013296.","journal-title":"Leukemia Research"},{"issue":"1","key":"7_CR77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","volume":"48","author":"L Kostakoglu","year":"2018","unstructured":"Kostakoglu, L., & Chauvie, S. (2018). Metabolic tumor volume metrics in lymphoma. Seminars in Nuclear Medicine, 48(1), 50\u201366.","journal-title":"Seminars in Nuclear Medicine"},{"issue":"30","key":"7_CR78","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","volume":"34","author":"H Schoder","year":"2016","unstructured":"Schoder, H., & Moskowitz, C. (2016). Metabolic tumor volume in lymphoma: Hype or hope? Journal of Clinical Oncology, 34(30), 3591\u20133594.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"7_CR79","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12149-011-0562-3","volume":"26","author":"T Watabe","year":"2012","unstructured":"Watabe, T., et al. (2012). Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET\/CT. Annals of Nuclear Medicine, 26(3), 222\u2013227.","journal-title":"Annals of Nuclear Medicine"},{"issue":"15","key":"7_CR80","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau, A. S., et al. (2016). Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clinical Cancer Research, 22(15), 3801\u20133809.","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"7_CR81","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","volume":"4","author":"L Ceriani","year":"2020","unstructured":"Ceriani, L., et al. (2020). SAKK38\/07 study: Integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Advances, 4(6), 1082\u20131092.","journal-title":"Blood Advances"},{"issue":"10","key":"7_CR82","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/bloodadvances.2020001816","volume":"4","author":"H Senjo","year":"2020","unstructured":"Senjo, H., et al. (2020). High metabolic heterogeneity on baseline 18FDG-PET\/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. Blood Advances, 4(10), 2286\u20132296.","journal-title":"Blood Advances"},{"issue":"2","key":"7_CR83","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","volume":"132","author":"L Ceriani","year":"2018","unstructured":"Ceriani, L., et al. (2018). Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood, 132(2), 179\u2013186.","journal-title":"Blood"},{"issue":"30","key":"7_CR84","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan, M., et al. (2016). Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. Journal of Clinical Oncology, 34(30), 3618\u20133626.","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"7_CR85","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","volume":"32","author":"D Albano","year":"2018","unstructured":"Albano, D., et al. (2018). Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma. Annals of Nuclear Medicine, 32(8), 532\u2013541.","journal-title":"Annals of Nuclear Medicine"},{"issue":"1","key":"7_CR86","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1148\/radiol.09090603","volume":"254","author":"G Storto","year":"2010","unstructured":"Storto, G., et al. (2010). Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology, 254(1), 245\u2013252.","journal-title":"Radiology"},{"issue":"8","key":"7_CR87","first-page":"1267","volume":"47","author":"JF Bruzzi","year":"2006","unstructured":"Bruzzi, J. F., et al. (2006). Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT. Journal of Nuclear Medicine, 47(8), 1267\u20131273.","journal-title":"Journal of Nuclear Medicine"},{"issue":"18","key":"7_CR88","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","volume":"123","author":"L Falchi","year":"2014","unstructured":"Falchi, L., et al. (2014). Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood, 123(18), 2783\u20132790.","journal-title":"Blood"},{"issue":"6","key":"7_CR89","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/leu.2015.21","volume":"29","author":"FR Mauro","year":"2015","unstructured":"Mauro, F. R., et al. (2015). Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia, 29(6), 1360\u20131365.","journal-title":"Leukemia"},{"issue":"2","key":"7_CR90","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.celrep.2019.03.036","volume":"27","author":"T Nguyen","year":"2019","unstructured":"Nguyen, T., et al. (2019). Uncovering the role of N-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. Cell Reports, 27(2), 491\u2013501. e6.","journal-title":"Cell Reports"}],"updated-by":[{"DOI":"10.1007\/978-3-030-65768-0_19","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000}}],"container-title":["Advances in Experimental Medicine and Biology","The Heterogeneity of Cancer Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-65768-0_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T06:08:07Z","timestamp":1649830087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-65768-0_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030657673","9783030657680"],"references-count":90,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-65768-0_7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/978-3-030-65768-0_19","asserted-by":"object"}]},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"21 May 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"22 October 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"After initial publication of the book, various errors were identified that needed correction. All corrections listed below have been updated within the current version.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}